Axumin
Active Ingredient(s): FluciclovineFDA Approved: * May 27, 2016
Pharm Company: * BLUE EARTH DIAGNOSTICS LTD
Category: Diagnostic Aid
* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".
Axumin Overview
Fluciclovine (18F), also known as anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (FACBC),[1][2] or as Axumin (brand name), and colloquially as anti-3[18F] FACBC or F18, is a diagnostic agent "indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels."[3][4] Contents 1 Background 2 Mechanism 3 Marketing 4 References ...
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Fluciclovine
Recent Axumin Forums:
Be the first to start a discussion about this drug.Possible Dosages for this and Related Drugs:
Fluciclovine
- Injection: 335-8200 Mbq/ml (9-221 Mci/ml)
- Solution: 9-221mci/ml
NDC Database Records for Axumin: (1 result)
Sorted by National Drug Code- 69932-001 Axumin 221 mci/Ml Intravenous Injection, Solution by Blue Earth Diagnostics